Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
First nine months 2020 results presentation
Operating income, growth figures, profitability and how our products have behaved.
Thu, 05/11/2020 - 00:00
0 min
Español
6S3A6968(3).jpg
Download related document
Select rating
Give First nine months 2020 results presentation 1/5
Give First nine months 2020 results presentation 2/5
Give First nine months 2020 results presentation 3/5
Give First nine months 2020 results presentation 4/5
Give First nine months 2020 results presentation 5/5
No votes yet
Related
ROVI achieves a 10% increase in operating income and 55% in net profit
Laboratorios Farmacéuticos Rovi, SA (BME: ROVI), company Pan-European pharmaceutical company specialized and dedicated to the research,...
5 min
24/02/2021
ROVI completes the manufacture of the first batches of Moderna vaccine
0 min
13/01/2021
ROVI completes the manufacture of the first batches of Moderna vaccine for EU
Laboratorios Farmacéuticos Rovi, S.A. (BME -Spanish Stock Exchanges and Markets: ROVI), a pan-European specialised company engaged in the...
2 min
13/01/2021
See More
Email
Facebook
Twitter
LinkedIn
6S3A6968(3).jpg